Bone marrow Immune globulin (intra-500 mg/kg IV on days 7 and 2 prior to Prophylaxis to decrease the risk of infection, interstitransplantation venous [IV])2 transplantation and then once weekly tial pneumonia, and acute graft-versus-host disease through day 90 after transplantation. in adults undergoing bone marrow transplantation.
Botulism Botulism antitoxin hep-Consult the CDC.3 Treatment of symptomatic botulism. Available from tavalent equine, Types the CDC.3 Incidence of serum reactions is <1%. A–G
Botulism immune 75 mg/kg IV. For the treatment of patients <1 year of age with globulin (IV) infant botulism caused by toxin type A or B.
Chronic Immune globulin (IV)2 400 mg/kg IV every 3–4 weeks. Dosage CLL patients with hypogammaglobulinemia and a lymphocytic should be adjusted upward if bacterial history of at least one serious bacterial infection. leukemia (CLL) infections occur.
Cytomegalovi-Cytomegalovirus Consult the manufacturer’s dosing Prophylaxis of CMV infection in bone marrow, kidney, rus (CMV) immune globulin (IV) recommendations. liver, lung, pancreas, and heart transplant recipients.
Diphtheria Diphtheria antitoxin, 20,000–100,000 units IV or IM Early treatment of respiratory diphtheria. Available equine depending on the severity and duration from the CDC.3 Anaphylactic reactions in ≥7% of of illness. adults and serum reactions in ≥5–10% of adults.
Hepatitis A Immune globulin (intra-Preexposure prophylaxis: 0.02 mL/kg muscular [IM]) IM for anticipated risk of ≥3 months, 0.06 mL/kg for anticipated risk of >3 months, repeated every 4–6 months for continued exposure.
Postexposure: 0.02 mL/kg IM as soon as possible after exposure up to 2 weeks.
Hepatitis B Hepatitis B immune 0.06 mL/kg IM as soon as possible after globulin (HBIG) exposure up to 1 week for percutaneous exposure or 2 weeks for sexual exposure. 0.5 mL IM within 12 hours after birth for perinatal exposure.
HIV-infected Immune globulin (IV)2 400 mg/kg IV every 28 days. children
Preexposure and postexposure hepatitis A prophylaxis. The availability of hepatitis A vaccine has greatly reduced the need for preexposure prophylaxis. Patients >40 years should receive hepatitis A vaccine in addition to immune globulin for postexposure prophylaxis
Postexposure prophylaxis in nonimmune persons following percutaneous, mucosal, sexual, or perinatal exposure. Hepatitis B vaccine should also be administered.
HIV-infected children with recurrent serious bacterial infections or hypogammaglobulinemia.
Idiopathic Immune globulin (IV)2 Consult the manufacturer’s dosing Response in children with ITP is greater than in thrombocyto recommendations for the specific adults. Corticosteroids are the treatment of choice in penic purpura product being used. adults, except for severe pregnancy-associated ITP. (ITP)
Kawasaki Immune globulin (IV)2 400 mg/kg IV daily for 4 consecutive Effective in the prevention of coronary aneurysms. disease days within 4 days after the onset of For use in patients who meet strict criteria for illness. A single dose of 2 g/kg IV over Kawasaki disease. 10 hours is also effective.